Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of UCB0022 Formulations in Healthy Participants
NCT07220551Phase 1Completed
- Sponsor
- UCB
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glovadalen in Parkinson's disease (PD) (2 arms), sponsored by UCB. Primary endpoints: Area under the plasma concentration-time curve, Area under the plasma concentration-time curve from time 0 to t and 1 more. Started Oct 2025; status: completed.
02
Drugs
glovadalen
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07220551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220551.